# 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

> **NCT02182830** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 166 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Hypertension

## Interventions

- **DRUG:** Empagliflozin low dose
- **DRUG:** placebo
- **DRUG:** Empagliflozin high dose

## Key facts

- **NCT ID:** NCT02182830
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-25
- **Primary completion:** 2017-05-18
- **Final completion:** 2017-05-18
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2018-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02182830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02182830, "24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02182830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*